MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
基本信息
- 批准号:6377993
- 负责人:
- 金额:$ 31.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-01 至 2005-08-31
- 项目状态:已结题
- 来源:
- 关键词:DNA binding protein acute myelogenous leukemia apoptosis cell differentiation chimeric proteins chromosome translocation gene induction /repression genetic transcription immunofluorescence technique immunoprecipitation intermolecular interaction molecular oncology neoplasm /cancer genetics oncoproteins retinoid binding proteins tissue /cell culture transcription factor transport proteins yeast two hybrid system
项目摘要
DESCRIPTION: (Adapted from the investigator's abstract) The t(15;17)
translocation accounts for over 95 percent of all human acute promyelocytic
leukemia (APL) cases. This translocation fuses the PML gene with the nuclear
receptor for retinoic acid (RARa) and creates an oncogenic fusion protein,
PML-RARa. It is thought that PML-RARa may interfere with the function of
wild-type PML and RARa. Immunocytochemistry studies reveal the localization of
PML at discrete nuclear domains known as PML oncogenic domains (PODs), Kr
bodies, ND10, or nuclear bodies. While the exact function of the PODs remains
unclear, its structure is disrupted in t(15;17)-translocation APL cells,
suggesting an important roles for the PODs in APL. To investigate the function
of the PODs, they have screened for PML-interacting factors using the yeast
two-hybrid system. They have isolated three specific interacting proteins
including a previously demonstrated PML-modifier, SUMO-1, and two novel
proteins that are implicated in transcriptional regulation. In this project,
they will investigate the interactions of PML with these two novel cofactors.
Standard techniques including the yeast two-hybrid assay, GST pull down,
Far-Western blot, and immunofluorescence microscopy will be utilized to
establish the interaction of PML with these cofactors. Based on their
preliminary studies, they propose that these two cofactors are transcriptional
repressors. Experiments will be conducted to determine the mechanism of
transcriptional repression by these proteins. They propose that the roles of
PML and the PODs are to recruit these cofactors to the restricted PML domains
by protein-protein interaction with PML. They further propose that localization
of these cofactors to the PODs will lead to inactivation of their
transcriptional repressor function. These hypotheses will be tested by a
combination of transient transfection and immunocytochemistry studies. In
addition, they will investigate the role of these PML cofactors in APL, based
on observations that these two proteins also interact with the APL oncogenic
fusion protein, PML-RARa. Together, these studies should shed new lights into
the function of PML and its nuclear domains, as well as providing new insights
to the function and regulation of the new cofactors. A better understanding of
mechanism of APL at the molecular and cellular levels should lead to a more
effective diagnosis and treatment of this disease, as well as providing
implications for other malignancies.
描述:(改编自调查人员的摘要)t(15;17)
易位占所有人类急性早幼粒细胞白血病的95%以上
白血病(APL)病例。这种易位将PML基因与核融合在一起
维甲酸受体(RARA),并产生致癌融合蛋白,
PML-RARA。目前认为PML-RARA可能干扰了PML-RARA的功能。
野生型PML和RARA。免疫细胞化学研究揭示了细胞的定位
PML位于离散的核结构域,称为PML致癌结构域(Pod),Kr
遗体、ND10或核体。当吊舱的确切功能保持不变
不清楚,它的结构在t(15;17)易位的APL细胞中被破坏,
这表明豆荚在APL中发挥了重要作用。要研究其功能
在豆荚中,他们已经使用酵母筛选出PML相互作用的因子
双杂交系统。他们已经分离出三种特定的相互作用蛋白
包括先前证明PML修饰剂SUMO-1和两种新的
参与转录调控的蛋白质。在这个项目中,
他们将研究PML与这两个新辅助因子的相互作用。
标准技术包括酵母双杂交试验,GST下拉,
Far-Western印迹和免疫荧光显微镜将用于
建立PML与这些辅因子的相互作用。基于他们的
初步研究表明,这两个辅因子是转录因子。
抑制者。将进行实验以确定其作用机制。
这些蛋白质的转录抑制作用。他们提出,人类的角色
PML和Pod将这些辅因子招募到受限的PML区域
通过与PML的蛋白质-蛋白质相互作用。他们进一步建议本地化
这些辅因子对豆荚的作用将导致它们的失活
转录抑制因子功能。这些假设将通过一项
瞬时转基因和免疫细胞化学研究相结合。在……里面
此外,他们将调查这些PML辅助因子在APL中的作用,基于
观察到这两种蛋白也与致癌的APL相互作用
融合蛋白,PML-RARA。总之,这些研究应该会给我们带来新的曙光
PML的功能及其核域,以及提供新的见解
新辅因子的功能和调节。更好地理解
APL在分子和细胞水平的机制应导致更多的
本病的有效诊断和治疗,以及提供
对其他恶性肿瘤的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J DON CHEN其他文献
J DON CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J DON CHEN', 18)}}的其他基金
MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
- 批准号:
6769875 - 财政年份:2000
- 资助金额:
$ 31.59万 - 项目类别:
MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
- 批准号:
6522917 - 财政年份:2000
- 资助金额:
$ 31.59万 - 项目类别:
MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
- 批准号:
6166043 - 财政年份:2000
- 资助金额:
$ 31.59万 - 项目类别:
MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
- 批准号:
6709853 - 财政年份:2000
- 资助金额:
$ 31.59万 - 项目类别:
MOLECULAR BASIS OF ACUTE PROMYELOCYTIC LEUKEMIA
急性早幼粒细胞白血病的分子基础
- 批准号:
6802828 - 财政年份:2000
- 资助金额:
$ 31.59万 - 项目类别:
REGULATION AND FUNCTION OF NUCLEAR RECEPTOR COACTIVATORS
核受体共激活剂的调节和功能
- 批准号:
2752280 - 财政年份:1999
- 资助金额:
$ 31.59万 - 项目类别:
REGULATION AND FUNCTION OF NUCLEAR RECEPTOR COACTIVATORS
核受体共激活剂的调节和功能
- 批准号:
6708831 - 财政年份:1999
- 资助金额:
$ 31.59万 - 项目类别:
REGULATION AND FUNCTION OF NUCLEAR RECEPTOR COACTIVATORS
核受体共激活剂的调节和功能
- 批准号:
6150608 - 财政年份:1999
- 资助金额:
$ 31.59万 - 项目类别:
REGULATION AND FUNCTION OF NUCLEAR RECEPTOR COACTIVATORS
核受体共激活剂的调节和功能
- 批准号:
6350680 - 财政年份:1999
- 资助金额:
$ 31.59万 - 项目类别:
MOLECULAR ACTIONS OF NUCLEAR RECEPTOR COREPRESSOR SMRT
核受体 CorePressor SMRT 的分子作用
- 批准号:
6524609 - 财政年份:1998
- 资助金额:
$ 31.59万 - 项目类别:
相似海外基金
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10308327 - 财政年份:2021
- 资助金额:
$ 31.59万 - 项目类别:
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia
HIF1A-DNMT3A 轴在 AML1/ETO 驱动的急性髓性白血病中的作用
- 批准号:
10312810 - 财政年份:2020
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10687861 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Dissecting the mechanistic basis of response to combined decitabine and ipilimumab following hematopoietic stem cell transplantation for relapsed acute myelogenous leukemia
剖析造血干细胞移植治疗复发性急性髓性白血病后联合地西他滨和伊匹单抗反应的机制基础
- 批准号:
430138413 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Research Fellowships
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10388497 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
9814793 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10740923 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10524124 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10197848 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10434077 - 财政年份:2019
- 资助金额:
$ 31.59万 - 项目类别: